DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 04 · Volume 5 · July 1972 DOI: 10.1055/s-002-15208

Originalarbeiten

177
Coper, H.; Deyhle, G.; Fähndrich, Ch.; Fähndrich, E.; Rosenberg, L.; Strauss, S.; Blum, A.; Dufour, H.: Excretion of Vanillyl-Mandelic Acid, Homovanillic Acid, N-Methyl-Nicotinamide, and N-Methyl-2-Pyridone-5-Carboxamide in Urine of Voluntary Test Persons and Psychiatric Patients Before and After Administration of Methionine
187
Lidberg, L.: The Effect of Syntocinon® on Patients Suffering from Impotence
191
Park, S.; Burdock, E. I.; Gershon, S.: Importance of Adequate Dosage Determination of Drug Efficacy: Trial of a New Butyrophenone Compound on Acute Schizophrenics*
198
Strian, F.; Micheler, E.; Benkert, O.: Tremor Inhibition in Parkinson Syndrome After Apomorphine Administration Under L-Dopa and Decarboxylase-Inhibitor Basic Therapy
205
Rapp, W.: Preliminary Study of Perphenazine Enanthate in the Treatment of Chronic Schizophrenia
215
Voelkel, A.: Medikamentenmißbrauch – Anonyme präklinische Selbstbehandlung Drug abuse as anonymous preclinical self-therapy
219
Hesse, G.: N-Phenyl-N-benzyl-4-amino-1-methyl-piperidin-hydrochloride (Bamipine) combined with 1-Cyclohexyl-1-methyl-2-methyl-amino-ethane (CHP) as a psychotropic drug for the interval and terminal treatment of depressive syndroms. N-Phenyl-N-benzyl-4-amino-1-methylpiperidin-hydrochlorid (Bamipine) kombiniert mit 1-Cyclohexyl-1-methyl-2-methyl-amino-äthan (CHP)* als Psychopharmakon zur Intervall- und Terminalbehandlung depressiver Syndrome